BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18191333)

  • 1. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
    Livi L; Saieva C; Borghesi S; Paoletti L; Meattini I; Rampini A; Petrucci A; Scoccianti S; Paiar F; Cataliotti L; Leonulli BG; Bianchi S; Biti GP
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):705-9. PubMed ID: 18191333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
    Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
    Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
    Arcangeli G; Pinnarò P; Rambone R; Giannarelli D; Benassi M
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):161-7. PubMed ID: 16226397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
    Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Breteau N; Body G; Azria D; Le Floch O; Calais G
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):324-32. PubMed ID: 16542788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
    Han S; Kim J; Sohn S; Kwak GH; Kim JY; Park K
    J Surg Oncol; 2007 Jan; 95(1):45-50. PubMed ID: 17192866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group.
    Benchalal M; Le Prisé E; de Lafontan B; Berton-Rigaud D; Belkacemi Y; Romestaing P; Peignaux K; Courdi A; Monnier A; Montcuquet P; Goudier MJ; Marchal C; Chollet P; Abadie-Lacourtoisie S; Datchary J; Veyret C; Kerbrat P
    Cancer; 2005 Jul; 104(2):240-50. PubMed ID: 15948160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
    J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
    Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
    J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of radiation boost after whole-breast radiotherapy.
    Livi L; Borghesi S; Saieva C; Fambrini M; Iannalfi A; Greto D; Paiar F; Scoccianti S; Simontacchi G; Bianchi S; Cataliotti L; Biti G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1029-34. PubMed ID: 19395193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients.
    Mladenovic J; Susnjar S; Gavrilovic D; Borojevic N
    J BUON; 2007; 12(2):215-20. PubMed ID: 17600875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor location, interval between surgery and radiotherapy, and boost technique influence local control after breast-conserving surgery and radiation: retrospective analysis of monoinstitutional long-term results.
    Knauerhase H; Strietzel M; Gerber B; Reimer T; Fietkau R
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1048-55. PubMed ID: 18359170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local recurrence in breast cancer after conservative surgery: timing of radiotherapy and sequencing of chemotherapy.
    Donato V; Monaco A; Messina F; De Sanctis V; Messineo D; Banelli E; Maurizi Enrici R
    Anticancer Res; 2004; 24(2C):1303-6. PubMed ID: 15154664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis.
    McDonald MW; Godette KD; Butker EK; Davis LW; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1031-40. PubMed ID: 18440727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
    Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.